Navigation Links
Par Pharmaceutical Companies Reports Third Quarter 2011 Results
Date:11/2/2011

p>

9,61010,14528,39737,457Selling, general and administrative

35,76250,302128,863140,402Settlements and loss contingencies, net

-2,312190,560(1,694)Restructuring costs

--26,986-Total operating expenses

45,37262,759374,806176,165Gain on sale of product rights and other

-79-6,000Operating income (loss)

39,73240,614(81,023)108,098Gain on marketable securities and other
investments, net

-3,567-3,567Interest income

160341965942Interest expense

(150)(928)(451)(2,754)Income (loss) from continuing operations before
provision for income taxes

39,74243,594(80,509)109,853Provision (benefit) for income taxes

17,68712,933(2,900)34,731Income (loss) from continuing operations

22,05530,661(77,609)75,122Discontinued operations:Provision (benefit) for income taxes

127127380(105)(Loss) income from discontinued operations

(127)(127)(380)105Net income (loss)

$21,928$30,534($77,989)$75,227Basic earnings (loss) per share of common stock:Income (loss) from continuing operations

$0.61$0.89($2.16)$2.20(Loss) income from discontinued operations

(0.00)(0.00)(0.01)0.00Net income (loss)  

$0.61$0.89($2.17)$2.20Diluted earnings (loss) per share of common stock:Income (loss) from continuing operations

$0.60$0.86($2.16)$2.12(Loss) income from discontinued operations

(0.00)(0.00)(0.01)0.00Net income (loss)  

$0.60$0.86($2.17)$2.12Weighted average number of common shares
outstanding:  Basic

36,14334,31035,87534,117  Diluted

36,77435,68435,87535,410Reconciliation Between Reported (GAAP); Adjusted Income (Loss) from Continuing Operations and "Cash EPS"(In Thousands, Except Per Share Data)(Unaudited)Three Months EndedSeptember 30,September 30,20112010Income from Continuing Operations$22,055$30,661Transaction costs for Edict and Anchen

2,852-Upfront and development milestone payments

-2,000Litigation
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced ... Global Industry Analysis, Size, Share, Growth, Trends And Forecast, ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... patients in order to treat dental impairments, for tooth ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... Medical Center is,seeking local residents with type 2 ... clinical study evaluating an investigational,device, the TANTALUS System. ... The TANTALUS System is an implantable device that ... eats. The primary objective of the,randomized, double-blind controlled ...
... Phase 3 Results Released at American Society of ... Genta,Incorporated (Nasdaq: GNTA ) announced the ... of patients in the Company,s randomized Phase,3 trial ... chronic lymphocytic leukemia (CLL). The new data show ...
Cached Medicine Technology:Vanderbilt Medical Center Seeks Middle Tennesseans with Type 2 Diabetes Who are Overweight for National Clinical Trial 2Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission 2Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission 3Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission 4Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission 5Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission 6
(Date:7/10/2014)... Low-fat cheeses and cakes that are just as ... supermarket shelves, thanks to fresh insights into how ... and texture. , Funded by the Engineering ... at Heriot-Watt University and the University of Edinburgh ... into micro-particles and therefore closely mimic the behaviour ...
(Date:7/10/2014)... experience hot flashes are unlikely to talk much about ... suffering if they are willing to try an ... case study., After seven weeks of hypnotic relaxation therapy, ... prostate cancer surgery showed a drastic decrease not only ... sleep quality, according to the study., The Baylor study ...
(Date:7/9/2014)... -- The World Health Organization recommends that youth participate ... vigorous physical activity (MVPA) each day. Studies have ... school hours. Therefore, it stands to reason that ... In a new study scheduled for publication in ... time spent outdoors after school was positively associated with ...
(Date:7/9/2014)... For the first time, researchers have access to detailed ... uses health care. A new study, called Our Health ... unique challenges faced by urban Aboriginal people in Canada ... , The findings, published today in BMJ Open ... and the general population. , Researchers interviewed 554 First ...
(Date:7/9/2014)... Researchers at the Perelman School of Medicine at ... Park Cancer Institute have received an $8 million grant ... effects of photodynamic light therapy (PDT) in patients with ... that most often manifests itself in the lining of ... to asbestos. The grant will fund a clinical trial ...
Breaking Medicine News(10 mins):Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2
... are treated in an emergency department (ED) after being ... in another violent encounter soon afterward, according to a ... Academic Societies (PAS) annual meeting in Vancouver, British Columbia, ... adolescents growing up in urban environments, and many emergency ...
... Packard Children,s Hospital and Stanford University School of Medicine ... decrease in hospital-wide mortality rates can be associated with ... The system, launched at Packard Children,s in 2007, was ... at the hospital over an 18-month period, according to ...
... The United States ... recently announced a collaborative study to evaluate an increased risk of cancer among firefighters as ... ... States Fire Administration, or USFA, and the National Institute for Occupational Safety and ...
... cancer, researcher says , SUNDAY, May 2 (HealthDay News) -- ... can lead to severe liver damage later in life, a ... Miller School of Medicine noted that national data shows that ... the United States are infected with hepatitis C. Based on ...
... ... community of Westmont Living, Morgan Hill, CA. Westmont of Morgan Hill offers a ... or memory care. Our primary goal is always to meet each resident’s individual requirements, ... ...
... of Paget,s disease, a painful bone condition that affects up ... international team of scientists, led by the University of Edinburgh, ... which bone is repaired, providing an explanation of why the ... normal process of breaking down old bone and replacing it. ...
Cached Medicine News:Health News:Young assault victims often involved in subsequent violence 2Health News:Study shows for first time decrease in mortality associated with physician order entry system 2Health News:Study shows for first time decrease in mortality associated with physician order entry system 3Health News:Federal Agencies to Study Causes of Firefighters' Cancers 2Health News:Federal Agencies to Study Causes of Firefighters' Cancers 3Health News:Many Kids With Hepatitis C Are Missed 2Health News:Designer Makeover for a New Resident at Westmont of Morgan Hill 2Health News:Gene find offers hope of screening test for bone disease 2
Rosenbaum card fits in the pocket (3.5 by 6.5") and shows point, Jaeger and distance equivalents from 20/800 to 20/20. Uses numbers, directional Es and XO patterns. For use at 14" (35 mm). Includes f...
... contemporary reading card was designed by James ... of near point exercises including words, numbers ... 20/260, 20/200, 20/100, 20/65, 20/50, 20/40, 20/30, ... reading in English and metric, Jaeger, point ...
Standard reading test. "walked regularly..."...
Standard reading test. "Children should be..."...
Medicine Products: